GILD GILEAD SCIENCES, INC. Insider Trading

O'Day (then-CEO) sells 15,000 GILD shares for $1,971,846.68 under pre-arranged 10b5-1 plan; stock down 13.9% in 90 days

Daniel Patrick O'Day, who was CEO at the time of filing, executed 3 separate sales totaling 15,000 shares for $1,971,846.68 on 2026-06-01 at prices ranging from $131.10 to $132.97. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, meaning the sales were scheduled and not discretionary. His post-transaction holding of 617.6K shares represents a -2.4% reduction from his prior 632.6K shares. The stock is currently trading at $127.57, down 18.9% from its 52-week high of $157.29 and down 13.9% over the past 90 days. His prior sales at GILD show mixed results: two April 2026 sales were followed by 30-day gains of 5.8% and 4.8%, while his March and February 2026 sales experienced 30-day declines ranging from -4.7% to -7.9%.

Mercier (Chief Comm & Corp Aff Officer) sold 28,000 shares on 2026-05-15 for $3.7M under scheduled 10b5-1 plan from 2025-02-20.

Mercier executed 4 separate sales totaling 28,000 shares for $3,676,198.56 at blended average price $131.29 on 2026-05-15, reducing her holdings by 18.2% to 125,779 shares post-transaction. This sale was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-02-20, meaning it was scheduled rather than discretionary. Prior sales at GILD on 2026-02-17 and 2025-11-17 show mixed short-term outcomes but context here is the structured, non-opportunistic nature of the current filing. GILD trades at P/E 17.48 with $7.0B quarterly revenue and +2.4% annual growth; the stock is -17.6% from its 52-week high and -5.8% over 30 days.

Gilead CEO O'Day sells ~$1.3M in stock as shares pull back from recent highs

CEO Daniel Patrick O'Day sold approximately $1.3 million in Gilead stock across two transactions, disposing of roughly 1.6% of his holdings in a single day. The timing is notable: the stock has pulled back noticeably from its recent highs and sits meaningfully below where it traded three months ago, suggesting O'Day is selling into weakness rather than at peak valuations. While Gilead remains a financially healthy, profitable company with strong revenue generation, this sale by the top executive during a down period could signal either portfolio rebalancing or a cautious view on near-term momentum. The modest reduction in his stake—less than 2% of total holdings—indicates this is not a wholesale liquidation, but it does represent a net reduction in his personal conviction at a time when the stock faces headwinds.